Table 3.

Detailed characteristics of patients not achieving SVR12.

Characteristics	Study patients
	06K003	06K005	06K019	06K035	18C2027	18K024
SVR 12	No	No	No	No	No	No
Age, years	38	47	42	50	51	55
Gender	Female	Female	Male	Male	Male	Male
HCV/HIV transmission	PWID	Unknown	PWID	PWID	PWID	Unknown
Adherence	100%	100%	100%	100%	100%	100%
Adverse event	No	Constipation	Urinary tract infection	No	No	No
At baseline
HCV genotype	3b	6n	3b	2a	3b	3b
Previous anti-HCV treatment	No	Interferon plus ribavirin	No	No	No	No
HCV RNA, log10 IU/mL	3.5	6.7	3.7	6.6	7.0	6.9
HIV RNA	<20 copies/ml	<20 copies/ml	<20 copies/ml	<20 copies/ml	<20 copies/ml	<20 copies/ml
FIB-4 score	0.71	1.33	4.32	3.47	4.28	3.56
CD4 count	640	1486	127	713	244	295
At relapse
HCV RNA, log10 IU/mL	6.7	5.7	1.9	6.3	5.3	6.8
FIB-4 score	1.07	1.97	6.58	2.11	3.87	2.43
CD4 count	971	762	145	Unavailable	448	236
HIV RNA	<20 copies/ml	<20 copies/ml	<20 copies/ml	<20 copies/ml	<20 copies/ml	<20 copies/ml

Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; PWID, people who inject drugs; FIB-4 Fibrosis 4 marker.